Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing
Science Advances · 18.07.2025 · 11 (29)
DOI: 10.1126/sciadv.adt1644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 18.07.2025. Verfasst von Gemma Valcárcel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetic Control of Haematopoiesis Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, 08916 Badalona, Spain. Hauptthemen laut MEDLINE: DNA Methylation, Gene Editing, Inflammation, CRISPR-Cas Systems. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune cell differentiation and activation are associated with widespread DNA methylation changes; however, the causal relationship between these changes and their impact in shaping cell fate decisions still needs to be fully elucidated. Here, we conducted a genome-wide analysis to investigate the relationship between DNA methylation and gene expression at gene regulatory regions in human immune cells. By using CRISPR-dCas9-TET1 and -DNMT3A epigenome editing tools, we successfully established a cause-and-effect relationship between the DNA methylation levels of the promoter of the interleukin-1 receptor antagonist ( IL1RN ) gene and its expression. We observed that modifying the DNA methylation status of the IL1RN promoter is sufficient to alter human myeloid cell fate and change the cellular response to inflammatory and pathogenic stimuli. Collectively, our findings demonstrate the potential of targeting specific DNA methylation events to directly modulate immune and inflammatory responses, providing a proof of principle for intervening in a broad range of inflammation-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Epigenetic Control of Haematopoiesis Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, 08916 Badalona, Spain.
- Doctoral Program in Biomedicine, Universitat de Barcelona (UB), 08036 Barcelona, Spain.
- Epigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, 08916 Badalona, Spain.
- Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai 200241, China.
ORCID-Profile: Gemma Valcárcel, Aleksey Lazarenkov, Anna V López-Rubio, Clara Berenguer, Josep Calafell-Segura, Javier Rodríguez-Ubreva, Esteban Ballestar, José Luis Sardina
Zitieren
APA
Valcárcel, G., Lazarenkov, A., López-Rubio, A. V., Berenguer, C., Calafell-Segura, J., Rodríguez-Ubreva, J., Ballestar, E., & Sardina, J. L. (2025). Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing. Science Advances, 11(29). https://doi.org/10.1126/sciadv.adt1644
Vancouver
Valcárcel G, Lazarenkov A, López-Rubio AV, Berenguer C, Calafell-Segura J, Rodríguez-Ubreva J, et al. Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing. Science Advances. 2025;11(29). doi:10.1126/sciadv.adt1644
BibTeX
@article{Valcrcel2025,
author = {Valcárcel, Gemma and Lazarenkov, Aleksey and López-Rubio, Anna V and Berenguer, Clara and Calafell-Segura, Josep and Rodríguez-Ubreva, Javier and Ballestar, Esteban and Sardina, José Luis},
title = {Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {29},
doi = {10.1126/sciadv.adt1644}
}
EUVIMED